Fri, Jan 30, 2015, 7:41 AM EST - U.S. Markets open in 1 hr 49 mins


% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • larshansson18 larshansson18 Feb 17, 2009 3:48 PM Flag

    OPEN LETTER to EpiCept Managament

    Excuse me for my hasty English in the last post. Maybe this will be worse:

    1. I hope the CEO is not the one designing the trials in the CO. My experience is that it is not right now.

    2. I do not have the full picture to evaluate the past. I do not see any problems today that forces me to have a view of that, given time is a scarcity. My own opinion about the NP-1 trials as they are described in the annual reports is that they seems OK. Different tests for several criterias along with recommendations from FDA. I presume the fas III on cancer pain also are testing how long the compunds stay in the blood, the problem arised by FDA that the CO have to straiten out.
    I have proposed that the cause for that they only got a 0.07 significanse in the test for "common nervpain" (name?) is that the group of patients have lose ends when the pain fades out. If you have a cronical pain like PHN then you notice when it dissapear. The significant difference to placebo will become more evident.

    The market for cancer and PHN is huge. In cancer pain there are no competitors.

    I have hard to see any contradictions about this? :-)

    3. Myriad and Epicept have a committe following Azixa. Of course are we not informed of everything.

    4. Azixa is in fas II and Myriads CEO have stated that the trial will transform direct over to a registration pivotal trail. FDA is pushing for that to happen, according to the webcast last fall. Azixa is the only therapy that have been crossing the blood barriare. The compound is 15 times more concentrated in the brain than in rest of the plasma in the body. Look at the presentations on Myriads homepage.

    5. "2407 is lightyears away from any value."
    2004 this VDA was noticed to completly wipe out the tumors together with another existing medicine in the market. As a VDA it really was something special the report stated.
    In Sweden there are (small) Cos that have farmed out early stages of patents for lots of money. Our patent is still undiluted.

    6. "Do you really think in current EPCT and market situation - EPCT
    gets 30% and upfronts etc ? Why ?"

    Look at the Genmab - Glaxo deal. I think that deal is a complicated mixture of cash - controllpost - royalty and later milstones - given future hits(some of these trails are in problems). The total deal was som 2.1 billion USD. 25% was the royalty.
    How confident are you in the future success? How much cash are you forced to show to crying shorters among the shareholders? Is it possible for you to translate my writing on There is quite a lot about this there.

    The big Ph will not produce only distribute the drug. The demand is easy to allocate geografically.

    7. "And do you think its a normal process that an undervalued company with
    a market approved cancer product has a 50c share with daily falling ?"

    No. That's why I have invested in the CO.

    I like the product and I do not fear the management to that degree that you do.
    My investment is big for me. It has been a success so far.

    I mentioned Hellstrand, as the man of honnor he seems to be - I take the back of him. The day I find that management perhaps not perform the way I like, I have to studie the past of yours. But before that I've used my feets and leave.

    Instead of leaving I am still buying. The day before yesterday, par example. That is of course a decision completly of my own. Noway, that I ever will see myself as a victime.

    Not after writing this anyway. ;-)

    Best regards and thanx for you concrete and correct attitude,


1.80-0.02(-1.10%)Jan 29 3:45 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.